Validity of the malnutrition screening tool as an effective predictor of nutritional risk in oncology outpatients receiving chemotherapy

Support Care Cancer. 2006 Nov;14(11):1152-6. doi: 10.1007/s00520-006-0070-5. Epub 2006 Apr 19.

Abstract

Goals of work: To determine the relative validity of the Malnutrition Screening Tool (MST) compared with a full nutrition assessment by the scored Patient Generated-Subjective Global Assessment (PG-SGA) and to assess MST inter-rater reliability in patients receiving chemotherapy.

Patients and methods: An observational, cross-sectional study was conducted at an Australian public hospital in 50 oncology outpatients receiving chemotherapy. Inter-rater reliability was assessed in a subsample of 20 patients.

Main results: According to PG-SGA global rating, the prevalence of malnutrition was 26%. The MST was a strong predictor of nutritional risk relative to the PG-SGA (100% sensitivity, 92% specificity, 0.8 positive predictive value, 1.0 negative predictive value). MST inter-rater reliability was acceptable with agreement by administration staff/nursing staff/patient and the dietitian in 18/20 cases (kappa=0.83; p0.001).

Conclusion: The MST has acceptable relative validity, inter-rater reliability, sensitivity, and specificity to identify chemotherapy outpatients at risk of malnutrition and, hence, is an acceptable nutrition screening tool in this patient population.

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / therapeutic use*
  • Australia / epidemiology
  • Body Mass Index
  • Cross-Sectional Studies
  • False Positive Reactions
  • Female
  • Humans
  • Male
  • Malnutrition / diagnosis*
  • Malnutrition / epidemiology*
  • Malnutrition / etiology
  • Mass Screening*
  • Middle Aged
  • Neoplasms / complications*
  • Neoplasms / drug therapy*
  • Neoplasms / epidemiology
  • Nutrition Assessment
  • Observer Variation
  • Outpatients*
  • Prevalence
  • Reproducibility of Results
  • Research Design
  • Risk Factors
  • Sensitivity and Specificity
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • Antineoplastic Agents